Novartis Investigative Site

Cambridge, Cambridgeshire CB23 3RE

0 studies enrolling now · 6 studies all time

What they study most

Idiopathic Pulmonary Fibrosis, Neoplasms, Breast, Pulmonary Arterial Hypertension

Studies at this site

• Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis — Stopped early
• Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients — Stopped early
• Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients — Stopped early
• EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer — APPROVED_FOR_MARKETING
• Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH) — Stopped early
• Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension — Completed